From 26c2c1bda37855e5d61f086932637a9e2d6c8fa6 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 17:57:35 +0000 Subject: [PATCH] extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...ients-undermining-chronic-use-economics.md | 6 ++++ ...eating-largest-per-patient-cost-savings.md | 6 ++++ ...rofits from health rather than sickness.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 17 +++++++++- 5 files changed, 66 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 40852332c..29698538f 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -77,6 +77,12 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon data shows adherence is the binding variable for GLP-1 cost-effectiveness: adherent users (80%+) show significantly stronger outcomes across all endpoints. For diabetes patients, medical cost growth is 6 points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months, but 7 points lower with consistent use. MACE reductions also scale with adherence. This confirms that the low persistence rates documented elsewhere directly undermine the economic case for GLP-1s. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 278f2b9b6..a785d47a4 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's real-world data confirms multi-organ protection extends to multiple systems: female users showed 47% MACE reduction, male users 26% reduction, plus lower rates of osteoporosis, rheumatoid arthritis, and certain pancreatic disorders. The temporal cost pattern (costs up 23% in year 1, then growth slows to 2% vs. 6% for non-users) provides the economic mechanism for how organ protection translates to cost savings—but only for long-term risk-bearers. + --- Relevant Notes: diff --git a/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md b/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md index 76ac1f575..d532c1739 100644 --- a/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md +++ b/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md @@ -315,6 +315,12 @@ The BALANCE Model is the first federal policy explicitly designed to test the pr WHO's three-pillar framework mirrors the attractor state architecture: (1) creating healthier environments through population-level policies = prevention infrastructure, (2) protecting individuals at high risk = targeted intervention, (3) ensuring access to lifelong person-centered care = continuous monitoring and aligned incentives. The WHO explicitly positions GLP-1s within this comprehensive system rather than as standalone pharmacotherapy, confirming that medication effectiveness depends on embedding within structural prevention infrastructure. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +GLP-1 cost dynamics provide direct evidence for the payment alignment thesis: medical costs rise 23% in year 1 (drug costs dominate) then grow just 2% vs. 6% for non-users in year 2+ (downstream savings kick in). Short-term payers (employers with turnover) see only costs. Long-term risk-bearers (MA plans, capitated systems) capture savings. This is a concrete example of how prevention-first economics require aligned payment structures—the same intervention is inflationary or cost-saving depending solely on who bears the risk. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..c65d126b6 --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-18" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..242e36838 100644 --- a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users +- After 12 months: medical costs grow 2% vs. 6% for non-users +- Diabetes indication at 30 months: medical cost growth 6 points lower; 9 points lower with 80%+ adherence +- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% MACE reduction in women, 26% in men +- Study released January 13, 2026